Isis VP-Corporate Development Kate Winkler Corcoran: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses the firm’s relationship with Alnylam, diabetes pipeline and maintaining independence.
You may also be interested in...
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists
Firm’s lead molecule, miR-122, could be in clinic to treat hepatitis C within two to three years, Isis CEO tells “The Pink Sheet” DAILY.
Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists
Firm’s lead molecule, miR-122, could be in clinic to treat hepatitis C within two to three years, Isis CEO tells “The Pink Sheet” DAILY.